The association of endoscopic and histologic endpoints with faecal calprotectin and C-reactive protein in patients with moderately to severely active ulcerative colitis treated with mirikizumab

被引：0
|
作者：
Panaccione, R. [1 ]
Sapin, C. [2 ]
Chan-Diehl, F. W. [3 ]
Moses, R. E. [3 ]
Siegmund, B. [4 ]
Walsh, A. [5 ]
Kobayashi, T. [6 ]
Parambir, D. S. [7 ]
Travis, S. [8 ]
机构：
[1] Univ Calgary, Cumming Sch Med, Fac Med, Calgary, AB, Canada
[2] Eli Lilly France, Rheumatol Gastroenterol Real World Access Analyt, Neuilly Sur Seine, France
[3] Eli Lilly & Co, Gastroenterol, Indianapolis, IN USA
[4] Univ Med Berlin, Medizin Klin Gastroenterol Infektiol, Rheumatol Charite, Berlin, Germany
[5] Nuffield Hlth Manor Hosp, Translat Gastroenterol Unit, Oxford, England
[6] Kitasato Univ, Gastroenterol, Kitasato Inst Hosp, Tokyo, Japan
[7] Northwestern Univ, Gastroenterol & Hepatol, Feinberg Sch Med, Chicago, IL USA
[8] Univ Oxford, Nuffield Dept Med, Oxford, England
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP90
引用
收藏
页码：I167 / I168
页数：2
相关论文
共 50 条
  • [41] Sustained Symptom Control With Mirikizumab in Patients With Moderately-to-Severely Active Ulcerative Colitis in the LUCENT-2 Maintenance Trial
    Dignass, Axel
    Danese, Silvio
    Matsuoka, Katsuyoshi
    Ferrante, Marc
    Long, Millie
    Redondo, Isabel
    Gibble, Theresa Hunter
    Moses, Richard
    Li, Xingyuan
    Morris, Nathan
    Milch, Catherine
    Abreu, Maria T.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S558 - S558
  • [42] BUDGET IMPACT OF MIRIKIZUMAB-MRKZ IN THE TREATMENT OF ADULT PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS IN THE UNITED STATES
    Stargardter, Matthew
    Upadhyay, Navneet
    Raj, Sayooj
    Fisher, Deborah
    Creveling, Thomas
    Bires, Nicholas
    Johnson, Nate
    Milev, Sandra
    INFLAMMATORY BOWEL DISEASES, 2024, 30 : S43 - S44
  • [43] Ulcerative Colitis: Correlation of the Rachmilewitz Endoscopic Activity Index with Fecal Calprotectin, Clinical Activity, C-reactive Protein, and Blood Leukocytes
    Schoepfer, Alain M.
    Beglinger, Christoph
    Straumann, Alex
    Trummler, Michael
    Renzulli, Pietro
    Seibold, Frank
    INFLAMMATORY BOWEL DISEASES, 2009, 15 (12) : 1851 - 1858
  • [44] Extended induction response over time in patients with moderately-to-severely active Ulcerative Colitis treated with mirikizumab in the LUCENT-1 and-2 trials
    Rubin, D. T.
    Charabaty, A.
    Jairath, V.
    Walter, J.
    McGinnis, K.
    Moses, R.
    Maier, S.
    Escobar, R.
    Baygani, S.
    Zaremba-Pechmann, L.
    Kobayashi, T.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1641 - I1642
  • [45] EXTENDED INDUCTION RESPONSE OVER TIME IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB IN THE LUCENT-1 AND-2 TRIALS
    Rubin, David T.
    Charabaty, Aline
    Jairath, Vipul
    Walter, James
    McGinnis, Kim
    Moses, Richard
    Maier, Sebastian
    Escobar, Rodrigo
    Baygani, Simin
    Zaremba-Pechmann, Liliana
    Kobayashi, Taku
    GASTROENTEROLOGY, 2024, 166 (05) : S821 - S821
  • [46] Mirikizumab Exposure-Response Relationships in Patients with Moderately-to-Severely Active Ulcerative Colitis in Randomized Phase II and III Studies
    Friedrich, Stuart
    Chua, Laiyi
    Adams, David H.
    Crandall, Wallace
    Zhang, Xin Cindy
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (02) : 435 - 447
  • [47] SERUM C-REACTIVE PROTEIN AS AN INDICATOR OF ACTIVE ULCERATIVE-COLITIS EXTENT
    PRANTERA, C
    LORENZETTI, R
    DAVOLI, M
    PALLONE, F
    MARCHEGGIANO, A
    GASTROENTEROLOGY, 1987, 92 (05) : 1579 - 1579
  • [48] Deep ulcers are associated with increased C-reactive protein in active ulcerative colitis
    Riviere, P.
    Le Chevillier, A.
    Rullier, A.
    Marty, M.
    Schurr, E.
    Lapuyade, B.
    Celerier, B.
    Fernandez, B.
    Bessissow, T.
    Treton, X.
    Uzzan, M.
    Poullenot, F.
    Berger, A.
    Zerbib, F.
    Laharie, D.
    DIGESTIVE AND LIVER DISEASE, 2023, 55 (09) : 1194 - 1200
  • [49] COST-EFFECTIVENESS ANALYSIS OF MIRIKIZUMAB VERSUS USTEKINUMAB IN ADVANCED THERAPY EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE US
    Wang, Xuan
    Bakker, Lytske
    Upadhyay, Navneet
    Hartz, Susanne
    Treur, Maarten
    Svedbom, Axel
    INFLAMMATORY BOWEL DISEASES, 2024, 30 : S44 - S45
  • [50] CORRELATION OF FECAL CALPROTECTIN AND C-REACTIVE PROTEIN CONCENTRATIONS WITH CLINICAL OUTCOMES AND ENDOSCOPIC DISEASE ACTIVITY IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING INDUCTION THERAPY WITH ETRASIMOD
    Yarur, Andres J.
    Jairath, Vipul
    Zhang, Jinkun
    Panes, Julian
    Chiorean, Michael V.
    Peyrin-Biroulet, Laurent
    Vermeire, Severine
    Cabell, Chris
    Naik, Snehal
    Sandborn, William J.
    GASTROENTEROLOGY, 2019, 156 (06) : S1108 - S1109
12345